ETFs
C
CHRS
Coherus
1.005
+0.046+4.83%Opening13:00 10/20 EDT
OPEN/PREV CLOSE0.9600/0.9587
TODAY RANGE0.9550-1.030
VOL411.64K
MARKET CAP155.27M
52 WEEK RANGE0.9400-2.616
AVG VOL (3M)1.25M
% TURNOVER0.27%
TURNOVER--
P/E (TTM)-0.9733
% RANGE7.82%
EPS(TTM)-1.0326
P/E(FORWARD)-1.2104
P/B2.552
BVPS0.3938
DIVIDEND--
P/S2.887
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP122.50M
SHARES OUTSTANDING154.50M
NEXT EARNINGS11/04-11/09
FREE FLOAT121.89M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·09/23 17:01
Coherus Oncology Shares Down on Plans to Sell Biosimilar Assets
TipRanks·09/23 13:35
Coherus Oncology retains Oppenheimer to market legacy biosimilar assets
TipRanks·09/21 17:56
H.C. Wainwright Keeps Their Buy Rating on Coherus Biosciences (CHRS)
TipRanks·08/28 21:30
Coherus Biosciences Launches $50 Million ATM Equity Program
Seeking Alpha·08/19 17:48
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development
TipRanks·08/18 00:12
Coherus Earnings Call: Oncology Focus, Cash Trade‑Offs
TipRanks·08/17 21:47
Coherus Biosciences Secures New Term Loan, Refinances Debt
TipRanks·08/17 21:47
Coherus Biosciences Issues Contingent Value Rights Dividend
TipRanks·08/17 21:40
Coherus Oncology issuing special dividend of biosimilar contingent value rights
Dow Jones·08/17 21:33
Press Release: Coherus Oncology Announces Special -2-
Dow Jones·08/07 17:19
Coherus Oncology Is Maintained at Buy by Guggenheim
Dow Jones·08/07 17:19
Coherus Oncology Price Target Cut to $10.00/Share From $12.00 by Guggenheim
Benzinga·08/07 17:08
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10
Same Industry
Name/Symbol
Change%
Price